Matinas BioPharma (NYSEAMERICAN:MTNB) Posts Quarterly Earnings Results

Matinas BioPharma (NYSEAMERICAN:MTNB) posted its quarterly earnings data on Wednesday. The company reported ($0.03) earnings per share (EPS) for the quarter, Yahoo Finance reports.

Matinas BioPharma Price Performance

MTNB stock traded down $0.02 on Friday, hitting $0.27. 1,217,731 shares of the company’s stock traded hands, compared to its average volume of 2,114,206. The firm has a market cap of $58.88 million, a PE ratio of -2.26 and a beta of 1.52. Matinas BioPharma has a 1-year low of $0.11 and a 1-year high of $0.89.

Institutional Investors Weigh In On Matinas BioPharma

Several hedge funds have recently made changes to their positions in MTNB. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Matinas BioPharma in the 3rd quarter valued at approximately $98,000. Vanguard Group Inc. lifted its position in Matinas BioPharma by 6.4% in the 4th quarter. Vanguard Group Inc. now owns 9,317,838 shares of the company’s stock worth $2,015,000 after buying an additional 564,020 shares in the last quarter. Wells Fargo & Company MN lifted its position in Matinas BioPharma by 8,516.7% in the 2nd quarter. Wells Fargo & Company MN now owns 566,550 shares of the company’s stock worth $204,000 after buying an additional 559,975 shares in the last quarter. Millennium Management LLC purchased a new stake in Matinas BioPharma in the 4th quarter worth approximately $120,000. Finally, Private Advisor Group LLC bought a new stake in Matinas BioPharma in the 1st quarter valued at $92,000. Hedge funds and other institutional investors own 11.77% of the company’s stock.

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.